Navigation Links
Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Date:10/7/2008

SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced findings from its development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). The findings suggest measurable differences in the expression of particular biomarkers in blood samples between IBS and non-IBS patients. The identification of these biomarkers, combined with a proprietary algorithm, led to the development of PROMETHEUS IBS Diagnostic. These findings were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Orlando, Florida.

"PROMETHEUS IBS Diagnostic is an exciting advancement in the field of functional gastrointestinal disease," said Dr. Anthony Lembo, M.D., a gastroenterologist in the Division of Gastroenterology at Beth Israel Deaconess Medial Center and an Assistant Professor of Medicine at Harvard Medical School. "This test complements current symptom-based diagnostic practices by identifying patients with biomarker patterns consistent or inconsistent with IBS."

Following an extensive analysis of approximately 600 to 700 pathways, each containing hundreds of potential IBS biomarkers, Prometheus scientists identified 16 biomarkers that showed sufficient altered expression. The expression levels of these 16 biomarkers were then measured in a sample cohort of more than 1,700 patients and analyzed to reveal optimal IBS prediction with a final set of 10 biomarkers, including some that enable Prometheus' proprietary protection. These biomarkers are associated with one or more of the following pathways related to digestion: motility, brain-gut axis, neuronal regulation and immune function.

"IBS can be very difficult to definitively diagnose and is therefore often left untreated," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "PROMETHEUS IBS Diagnostic is the first in a series of tests we are developin
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
7. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
11. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... an underwritten public offering of its common stock consisting ... 2,459,175 shares to be sold by certain of its ... a 30-day option to purchase up to an additional ...
(Date:6/1/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... clinical data from its Phase I/II clinical trial ... multiforme (GBM), the most common and deadly form ...
(Date:6/1/2015)... 2015 CEFALY Technology , the creators ... specifically authorized for use prior to the onset of ... PET trial showing that the Cefaly device returns normal ... migraine patients, namely the orbitofrontal cortex and rostral cingulate. ... is an imaging test of the brain, used a radioactive substance called ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... National Entity to Address Workforce , WASHINGTON, ... congressional staff and representatives of national health care ... reform legislation does not yet reflect the strategic ... health system reform. "Pending bills include numerous ...
... 7 Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, ... Weinberg, Ph.D., a founding member of the Whitehead Institute ... MIT, has joined the company,s Scientific Advisory Board. ... human oncogene (the ras oncogene that causes ...
Cached Medicine Technology:Health Reform Bills Still Lack Strategic Focus on Health Workforce 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 3
(Date:6/2/2015)... FDA approved Orlistat for weight loss ... satisfactory doctor consultation. The less potent, over-the-counter version of Orlistat, ... has the longest track record as an FDA approved weight ... down fats in foods, Orlistat treatment prevents the body from ... be excreted through feces. , The most common ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Thermi, ... technology company has successfully transitioned into its new ... due to the company’s continued rapid worldwide expansion ... comprised of over 25 Thermi employees, including those ... development teams. , “As one of the fastest ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 While the ... adaptions of comic books, comic books themselves are stepping ... Comics Uniting Nations plans to produce educational comics in ... Global Goals for Sustainable Development - an international effort ... poverty, hunger, health, education, sustainable energy, inequality, climate change ...
(Date:6/2/2015)... SB 277 (CA Legislature, bit.ly/1Q0P8OY) will require ... public or private school. SB277 cleared three Senate policy ... Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). It passed ... “We believe that this bill affects the education of ... will (the) affect public health of California.. It is ...
(Date:6/2/2015)... “We want men to realize the importance of protecting ... Phillips, owner of SunGrubbies.com, “that is why we offer ... that work well for outdoor activities.” , The effects of ... can take up to thirty years to develop. The ... cancer to occur. That is why the simple act ...
Breaking Medicine News(10 mins):Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2
... Md., Aug. 12 The third annual Psoriasis Cure Now ... a theme of helping psoriasis patients connect with one another. ... patients to resist the social isolation that often results from ... with psoriasis and psoriatic arthritis to provide mutual support and ...
... French . , Montreal, August 12, 2009 Sounds ... according to a new Canadian study. In the online edition of ... PNAS ), scientists from the Universit de Montral and the Montreal ... in the brain allows people to distinguish between different types of ...
... ... of device, new trials , ... San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage ... permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials ...
... , , Milestone shows ... shows how much the culture has changed when reporting medical events , ... Safety Authority has collected over one million reports from Pennsylvania healthcare facilities ... events that did not cause harm to the patient. , , ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that ... correct the ownership of its intellectual property (IP) rights. ... five (5) issued patents, HTDS finds that the Company ...
... ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: VSCP ... financial results for the quarter and six months ended June 30, 2009. ... Revenues for the second quarter of 2009 increased 47% to $2.5 million, compared ... Gross profit for the second quarter of 2009 increased 96% to $1.4 ...
Cached Medicine News:Health News:Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 2Health News:Human mind: Sound and vision wired through same 'black box' 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 2Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 4Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 2Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 3Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 2Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 3Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 5Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 6Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 7Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 8Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 9
... of the Criterion precast gel system, allows you ... a single run. Criterion gels are wider and ... mini gel. They accommodate Bio-Rad's 11 cm ReadyStrip ... of separation and speed in 2-D electrophoretic applications. ...
... Mini-Vertical Gel System simplifies the process of separating ... It is able to run four gels at ... maximize utility and throughput, the 120 mini-vertical runs ... (W x L) at one time. The 120 ...
... High-Throughput (HTP) Protein Electrophoresis ... integrated pre-cast gel system ... protein analysis. It consists ... E-Base™ integrated power device, ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
Medicine Products: